Barclays initiates coverage of Boston Scientific stock at Equal-Weight
Published on 10/08/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Barclays initiated coverage at Equal-Weight on October 7, 2026, adding a fresh analyst view for Boston Scientific.
- Boston Scientific appointed Joseph Fitzgerald as chief operating officer effective January 1, 2027, alongside a three-segment structure.
- The Lang & Schwarz price was EUR 37.49 on October 8, 2026 at 4:40 p.m. CEST, minus 0.11 percent versus EUR 37.53.
Boston Scientific (ISIN US1011371077) was priced at EUR 37.49 at Lang & Schwarz on October 8, 2026 at 4:40 p.m. CEST, minus 0.11 percent versus the EUR 37.53 prior close. Fintel reported that Barclays initiated coverage on October 7, 2026 with an Equal-Weight recommendation.
Three milestones reset the story
On July 29, 2026, MarketBeat reported second-quarter revenue of USD 5.44 billion and adjusted earnings per share of USD 0.86, versus consensus of USD 0.83. Revenue increased 7.50 percent year over year, while adjusted earnings per share exceeded consensus by USD 0.03.
On October 5, 2026, MarketBeat said Citigroup cut its price target from USD 50.00 to USD 48.00 while keeping a Neutral rating. On October 7, 2026, Boston Scientific appointed Joseph M. Fitzgerald chief operating officer effective January 1, 2027.
Dates investors can measure
The next milestones are October 28, 2026, for the earnings report, according to Pluang, and January 1, 2027, when Fitzgerald's appointment and the new operating structure take effect, according to Boston Scientific.
What does the new structure change?
The company will create three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg. Fitzgerald will oversee global operations, business units and regions, giving the restructuring a direct operating owner rather than making it only a reporting change.
Stock stays near its yearly low
On the NYSE, Boston Scientific was last at USD 41.98 at 10:51 a.m. ET on October 8, 2026. Its market capitalization was USD 62.4 billion, and its 52-week range was USD 41.44 to USD 105.65 as of the same date.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock at a glance
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 4:40 p.m. CEST): EUR 37.49
- Change versus prior close: minus 0.11 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 37.53
- Market capitalization: USD 62.4 billion (as of October 8, 2026)
- 52-week range: USD 41.44-105.65 (as of October 8, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
